BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Primary Membranous Nephropathy readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Primary Membranous Ne
 phropathy\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07157787-11163@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270702
DTEND;VALUE=DATE:20270703
SUMMARY:ALXN1920: Phase 2 readout est. (NCT07157787)
DESCRIPTION:ALXN1920\, phase 2\, Primary Membranous Nephropathy.\nStudy: St
 udy of ALXN1920 in Adult Participants With Primary Membranous Nephropathy 
 (PMN)\nEstimated primary completion: 2 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/alxn1920#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07157787
URL:https://assetmemo.bio/drug/alxn1920#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07096843-10939@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:budoprutug: Phase 2 readout est. (NCT07096843)
DESCRIPTION:budoprutug\, phase 2\, Primary Membranous Nephropathy.\nStudy: 
 A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropa
 thy\nEstimated primary completion: October 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/budoprutug#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07096843
URL:https://assetmemo.bio/drug/budoprutug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06781944-2649@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT06781944)
DESCRIPTION:Obinutuzumab\, phase 3\, Primary Membranous Nephropathy.\nStudy
 : OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membra
 nous Nephropathy(Blossom Study)\nEstimated primary completion: 31 May 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/obinutuzumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06781944
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204275-10841@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290627
DTEND;VALUE=DATE:20290628
SUMMARY:Povetacicept: Phase 2/3 readout est. (NCT07204275)
DESCRIPTION:Povetacicept\, phase 2/3\, Primary Membranous Nephropathy.\nStu
 dy: Evaluation of Efficacy\, Safety\, and Tolerability of Povetacicept in 
 Participants With Primary Membranous Nephropathy (pMN)\nEstimated primary 
 completion: 27 June 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/povetacicept#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07204275
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962800-3402@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20300128
DTEND;VALUE=DATE:20300129
SUMMARY:Felzartamab: Phase 3 readout est. (NCT06962800)
DESCRIPTION:Felzartamab\, phase 3\, Primary Membranous Nephropathy.\nStudy:
  A Study to Learn More About the Effects and Safety of Felzartamab Infusio
 ns in Adults With Primary Membranous Nephropathy (PMN)\nEstimated primary 
 completion: 28 January 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/felzartamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06962800
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
